Rheumatoid Arthritis Information
More articles below:
Rheumatoid Arthritis a Threat to the Heart
Vaccine Reverses Type 1 Diabetes in Mice
Middle-Age Americans Less Mobile Than Ever
Long-Term Methotrexate Won't Help Kids With Juvenile Arthritis
Obesity, Alcohol Among Factors Linked to Women's Gout Risk
Many With Arthritis Find Simple Solutions for Relief
Actemra Approved for Rheumatoid Arthritis
MONDAY, Jan. 11 (HealthDay News) -- Actemra (tocilizumab) has been approved by the U.S. Food and Drug Administration to treat rheumatoid arthritis among people who haven't responded to, or who cannot tolerate, other approved RA drugs, the agency said Monday.
Actemra was approved for limited use because of adverse reactions noted in clinical trials, including the possibility of elevated liver enzymes, elevated "bad" cholesterol (LDL), hypertension, and gastrointestinal perforations, the agency said in a news release.
Actemra blocks an immune system protein called interleukin-6, which is found in excess in people with rheumatoid arthritis.
As a condition of the approval, San Francisco-based Genentech, the drug's marketer, must conduct additional clinical studies to evaluate the drug's long-term effectiveness and cardiovascular safety, the FDA said.
The agency said it also is requiring development of a Risk Evaluation and Mitigation Strategy for doctors, to inform physicians on how to monitor patients for possible liver or gastrointestinal side effects.
The most common adverse effects found in clinical testing included upper respiratory infections and other "serious" infections, headache, nasal and sinus inflammation, high blood pressure and increased liver enzymes, the agency said.
More information
The FDA has more about this approval.
DON'T HAVE Rx COVERAGE?Click Here to print out your FREE OPTIMIZERx Card and instantly begin savings on your next prescriptions!
